Clovis Oncology

Clovis acquires, develops and commercialises innovative anti-cancer drugs in the US, Europe and other international markets. The management team is comprised of the former executives of Pharmion, an earlier Abingworth portfolio company, which was acquired by Celgene for $2.9 billion in 2008. Clovis went public in November 2011.